Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD‐1/PD‐L1 axis

Immune checkpoint therapy to reverse natural killer (NK) and T cell exhaustion has emerged as a promising treatment in various cancers. While anti‐programmed cell death 1 (PD‐1) pembrolizumab has recently gained Food and Drug Administration (FDA) approval for use in recurrent or metastatic cervical...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Exp Immunol
Päätekijät: Solorzano‐Ibarra, F., Alejandre‐Gonzalez, A. G., Ortiz‐Lazareno, P. C., Bastidas‐Ramirez, B. E., Zepeda‐Moreno, A., Tellez‐Bañuelos, M. C, Banu, N., Carrillo‐Garibaldi, O. J., Chavira‐Alvarado, A., Bueno‐Topete, M. R., del Toro‐Arreola, S., Haramati, J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2021
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944364/
https://ncbi.nlm.nih.gov/pubmed/33306195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13561
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia